Sasaki K, Kantarjian HM, Kadia T, et al. - In patients with FLT3-internal tandem duplication (ITD)–mutated acute myeloid leukemia (AML), researchers ascertained if the addition of sorafenib to intensive induction chemotherapy improves outcomes. A total of 183 newly diagnosed patients with FLT3-ITD–mutated AML were identified between February 2001 and December 2017. In the sorafenib cohort, the overall response rate was 98% and the intensive chemotherapy cohort was 83%. In patients with FLT3-ITD–mutated AML, the addition of sorafenib improves survival regardless of whether they undergo allogeneic stem cell transplantation.